Log in

Relevant bibliographies by topics / Autologous HSCT / Journal articles

To see the other types of publications on this topic, follow the link: Autologous HSCT.

Journal articles on the topic 'Autologous HSCT'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Autologous HSCT.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Khalid Ahmed, Al-Anazi, E. Mutahar, O. Abduljalil, et al. "The outcome of autologous hematopoietic stem cell transplantation in patients with multiple myeloma. The experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia." Journal of Stem Cell Therapy and Transplantation 6, no. 1 (2022): 019–28. http://dx.doi.org/10.29328/journal.jsctt.1001027.

Full text

Abstract:

Background: Aautologous hematopoietic stem cell transplants (HSCT) is the standard of care for newly diagnosed patients with multiple myeloma (MM) who are eligible for autologous transplantation. Although cryopreservation is routinely employed, autologous HSCT can be performed using non-cryopreserved stem cells. Methods and materials: A retrospective study of patients with MM who received autologous HSCT between the 10th of October 2010 and the 31st of January 2022 at King Fahad Specialist Hospital (KFSH) in Dammam, Saudi Arabia was performed. Results: Over 11 years and 113 days, a total of 13

APA, Harvard, Vancouver, ISO, and other styles

2

Gratwohl, Alois, Helen Baldomero, Bruno Horisberger, Caroline Schmid, Jakob Passweg, and Alvaro Urbano-Ispizua. "Current trends in hematopoietic stem cell transplantation in Europe." Blood 100, no. 7 (2002): 2374–86. http://dx.doi.org/10.1182/blood-2002-03-0675.

Full text

Abstract:

Major changes have occurred in the transplantation of hematopoietic stem cells (HSCs) during the last decade. This report reveals the changes, reflects current status, and provides medium-term projections of HSC transplantation (HSCT) development in Europe. Data on 132 963 patients, 44 165 with allogeneic HSC transplant (33%) and 88 798 with an autologous HSC transplant (67%), collected prospectively from 619 centers by the European Group for Blood and Marrow Transplantation (EBMT) in 35 European countries between 1990 (4234 HSCTs) and 2000 (19 136 HSCTs) illustrate utilization of HSCT. HSCT i

APA, Harvard, Vancouver, ISO, and other styles

3

Khalid Ahmed, Al-Anazi, A. Alshami, E. Mutahar, et al. "Outcome of Outpatient Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma and Relapsed and Refractory Hodgkin Lymphoma. The Experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia." Journal of Stem Cell Therapy and Transplantation 7, no. 1 (2023): 003–15. http://dx.doi.org/10.29328/journal.jsctt.1001030.

Full text

Abstract:

Background: Autologous hematopoietic stem cell transplants (HSCT) is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (MM) and patients with relapsed and refractory Hodgkin lymphoma (R/R-HL) who achieve chemosensitivity after salvage therapy. Although autologous HSCT is routinely performed in an inpatient setting, the procedure can safely be performed in an outpatient setting. Methods and materials: A retrospective study of patients with MM and R/R- HL who received outpatient autologous HSCT at King Fahad Specialist Hospital (KFSH) in Dammam, Saudi Ar

APA, Harvard, Vancouver, ISO, and other styles

4

Rowe, Jacob M., Zhuoxin Sun, Peter A. Cassileth, et al. "Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG)." Blood 112, no. 11 (2008): 49. http://dx.doi.org/10.1182/blood.v112.11.49.49.

Full text

Abstract:

Abstract Over the past decade several prospective studies of post-remission therapy in AML have compared allogeneic hematopoietic stem cell transplantation (HSCT), autologous HSCT and chemotherapy. The data are appropriately presented by intention-to-treat analyses. However, such analyses do not provide information to the clinician or patient as to outcome from the initiation of post-remission therapy, be it HSCT or chemotherapy. Furthermore, such analyses are impossible to interpret when a significant percentage of patients do not receive their intended therapies (for example, only 54% of pat

APA, Harvard, Vancouver, ISO, and other styles

5

Snowden, John A. "Rebooting autoimmunity with autologous HSCT." Blood 127, no. 1 (2016): 8–10. http://dx.doi.org/10.1182/blood-2015-11-678607.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Verrecchia, Franck, and Dominique Farge. "Autologous HSCT: toward scleroderma treatment." Blood 110, no. 4 (2007): 1088–89. http://dx.doi.org/10.1182/blood-2007-05-089102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

van Laar, Jacob M., Svetlana I. Nihtyanova, Kamran Naraghi, Christopher P. Denton, and Alan Tyndall. "Autologous HSCT for systemic sclerosis." Lancet 381, no. 9883 (2013): 2079–80. http://dx.doi.org/10.1016/s0140-6736(13)61239-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Sakellari, Ioanna, Eleni Gavriilaki, Despoina Mallouri, Ioannis Batsis, and Achilles Anagnostopoulos. "Autologous HSCT for systemic sclerosis." Lancet 381, no. 9883 (2013): 2080. http://dx.doi.org/10.1016/s0140-6736(13)61240-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kohn, Donald B. "Eliminating SCID row: new approaches to SCID." Hematology 2014, no. 1 (2014): 475–80. http://dx.doi.org/10.1182/asheducation-2014.1.475.

Full text

Abstract:

Abstract Treatments for patients with SCID by hematopoietic stem cell transplantation (HSCT) have changed this otherwise lethal primary immune deficiency disorder into one with an increasingly good prognosis. SCID has been the paradigm disorder supporting many key advances in the field of HSCT, with first-in-human successes with matched sibling, haploidentical, and matched unrelated donor allogeneic transplantations. Nevertheless, the optimal approaches for HSCT are still being defined, including determining the optimal stem cell sources, the use and types of pretransplantation conditioning, a

APA, Harvard, Vancouver, ISO, and other styles

10

BOHGAKI, TOSHIYUKI, TATSUYA ATSUMI, MIYUKI BOHGAKI, et al. "Immunological Reconstitution after Autologous Hematopoietic Stem Cell Transplantation in Patients with Systemic Sclerosis: Relationship Between Clinical Benefits and Intensity of Immunosuppression." Journal of Rheumatology 36, no. 6 (2009): 1240–48. http://dx.doi.org/10.3899/jrheum.081025.

Full text

Abstract:

Objective.To analyze the relationship between clinical benefits and immunological changes in patients with systemic sclerosis (SSc) treated with autologous hematopoietic stem cell transplantation (HSCT).Methods.Ten patients with SSc were treated with high-dose cyclophosphamide followed by highly purified CD34+ cells (n = 5) or unpurified grafts (n = 5). Two groups of patients were retrospectively constituted based on their clinical response (good responders, n = 7; and poor responders, n = 3). As well as clinical findings, immunological reconstitution through autologous HSCT was assessed by fl

APA, Harvard, Vancouver, ISO, and other styles

11

Girmenia, Corrado, Alice Bertaina, Alfonso Piciocchi, et al. "Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey." Clinical Infectious Diseases 65, no. 11 (2017): 1884–96. http://dx.doi.org/10.1093/cid/cix690.

Full text

Abstract:

Abstract Background Gram-negative bacteremia (GNB) is a major cause of illness and death after hematopoietic stem cell transplantation (HSCT), and updated epidemiological investigation is advisable. Methods We prospectively evaluated the epidemiology of pre-engraftment GNB in 1118 allogeneic HSCTs (allo-HSCTs) and 1625 autologous HSCTs (auto-HSCTs) among 54 transplant centers during 2014 (SIGNB-GITMO-AMCLI study). Using logistic regression methods. we identified risk factors for GNB and evaluated the impact of GNB on the 4-month overall-survival after transplant. Results The cumulative inciden

APA, Harvard, Vancouver, ISO, and other styles

12

Fujita, Hiroyuki, Norio Asou, Masako Iwanaga, et al. "Role of Hematopoietic Stem Cell Transplantation As Salvage Treatment of Acute Promyelocytic Leukemia Initially Treated with All-Trans-Retinoic Acid: A Retrospective Analysis of the Japan Adult Leukemia Study Group (JALSG) APL97 Study." Blood 118, no. 21 (2011): 2036. http://dx.doi.org/10.1182/blood.v118.21.2036.2036.

Full text

Abstract:

Abstract Abstract 2036 BACKGROUND: There are limited numbers of studies focusing on the role of hematopoietic stem cell transplantation (HSCT) as a salvage treatment for acute promyelocytic leukemia (APL) after relapse in the all-trans-retinoic acid (ATRA) era. We retrospectively analyzed the outcomes of APL patients who underwent allogeneic or autologous HSCT during second complete remission (CR2) and compared them with those in APL patients who did not receive HSCT. PATIENTS & METHODS: A total of 302 adult patients with previously untreated de novo APL were registered in the Japan Adult

APA, Harvard, Vancouver, ISO, and other styles

13

Friedman, Debra L., Wendy Leisenring, Mary E. Flowers, Leona Holmberg, Jeffrey Schwartz, and H. Joachim Deeg. "Risk Factors for Second Malignancies after Transplantation Differ between Allogeneic and Autologous Transplantation." Blood 106, no. 11 (2005): 1121. http://dx.doi.org/10.1182/blood.v106.11.1121.1121.

Full text

Abstract:

Abstract Survivors of hematopoietic stem cell transplantation (HSCT) are at risk for second malignant neoplasms (SMN). We undertook this analysis to ascertain whether risk of SMN was comparable in survivors of allogeneic and autologous transplantation. Among 8662 transplant recipients treated at the Fred Hutchinson Cancer Research Center between November 1969 and April 2004, who survived at least 100 days post transplant, there were 1743 autologous and 6919 allogeneic HSCT recipients. Within this cohort, there were 56 SMNs among the autologous and 224 among the allogeneic recipients. Cumulativ

APA, Harvard, Vancouver, ISO, and other styles

14

Tichelli, André, Christoph Bucher, Alicia Rovó, et al. "Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation." Blood 110, no. 9 (2007): 3463–71. http://dx.doi.org/10.1182/blood-2006-10-054080.

Full text

Abstract:

Abstract We assessed incidence and risk factors of cardiovascular events in 265 patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT) between 1980 and 2000 and who survived at least 2 years. Results were compared with a cohort of 145 patients treated during the same period with autologous HSCT. The median age of patients with allogeneic HSCT at last follow-up was 39 years, and median follow-up was 9 years. Eighteen (6.8%) patients after allogeneic and 3 (2.1%) patients after autologous HSCT experienced an arterial event. The cumulative incidence of first arterial event

APA, Harvard, Vancouver, ISO, and other styles

15

Attolico, Imma, Francesco Tarantini, Paola Carluccio, et al. "Serological Response Following BNT162b2 Anti-Sars-Cov-2 mRNA Vaccination in Hematopoietic Stem Cell Transplantation Patients." Blood 138, Supplement 1 (2021): 4875. http://dx.doi.org/10.1182/blood-2021-147542.

Full text

Abstract:

Abstract Patients with hematological malignancies (HM) undergoing hematopoietic stem cell transplantation (HSCT) have an increased vulnerability to SARS-Cov-2 (Sharma et al, Lancet Haematology 2020; Ljungman et al, Leukemia 2021), the reason why international guidelines strongly support the need for a protective vaccination for these subjects. The most relevant data currently available on the response to a complete anti-SARS-Cov-2 vaccination cycle in HM patients after HSCT refer to 314 patients reported in a Lithuanian national survey (Maneikis et al, Lancet Haematol 2021). In this study, the

APA, Harvard, Vancouver, ISO, and other styles

16

Ali, Natasha, Raheel Iftikhar, Muhammad Ayaz Mir, et al. "Haematopoietic Stem Cell Transplant Trends in Pakistan: Activity Survey from Pakistan Bone Marrow Transplant Group." Journal of Transplantation 2023 (September 28, 2023): 1–6. http://dx.doi.org/10.1155/2023/8865364.

Full text

Abstract:

Pakistan is the fifth most populous country with a population of 225 million and has health expenditure accounting for only 2.8 percent of gross domestic product (GDP). Accordingly, there are a limited number of haematology-oncology and transplant centers in the country. The Pakistan Blood and Marrow Transplant (PBMT) group was established in 2020, and this report is the first activity survey from January 2021 to December 2022 focusing on the trends of matched-related donor, haploidentical, and autologous transplants in a developing country. A total of 12 transplant centers contributed data on

APA, Harvard, Vancouver, ISO, and other styles

17

Loberiza, Fausto R., Mei-Jie Zhang, Stephanie J. Lee, et al. "Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States." Blood 105, no. 7 (2005): 2979–87. http://dx.doi.org/10.1182/blood-2004-10-3863.

Full text

Abstract:

AbstractThe effect of the organization and delivery of health care at medical centers, referred to as “center effects,” with clinical outcomes after hematopoietic stem cell transplantation (HSCT) is not clear. We examined the association between center and treatment provider factors and mortality after HSCT. We surveyed 163 (87% response rate) United States transplantation centers that performed HLA-identical sibling HSCT for leukemia or autologous HSCT for lymphoma between 1998 and 2000 among patients at least 18 years old. One hundred thirteen (69%) centers performed HLA-identical sibling tr

APA, Harvard, Vancouver, ISO, and other styles

18

Burt, Richard K., Sanjiv J. Shah, James Schroeder, et al. "Autologous HSCT for systemic sclerosis – Authors'reply." Lancet 381, no. 9883 (2013): 2080–81. http://dx.doi.org/10.1016/s0140-6736(13)61241-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Manasvi, Patil Krushna Shinde. "An Overview on Pluripotent Stem Cell Genetic Transfer." International Journal of Pharma Research and Technology 1, no. 1 (2022): 1–16. https://doi.org/10.5281/zenodo.7461148.

Full text

Abstract:

In order to treat diseases like lymphoma, leukaemia, immune-deficiency disorders, congenital metabolic abnormalities, hemoglobinopathies, and myelodysplastic and myeloproliferative syndromes, more than 25,000 hematopoietic stem cell transplants (HSCTs) are carried out annually. Patients undergo extensive myeloablative chemoradiotherapy prior to transplantation, followed by stem cell "rescue." The patient's own hematopoietic stem cells, which are removed before to transplantation and reinfused following myeloablation, are employed in autologous HSCT. Human leukocyte antigen (HLA)-

APA, Harvard, Vancouver, ISO, and other styles

20

Jethani, Jyoti, Sameer Samad, Prashant Kumar, and Lalit Dar. "Risk of respiratory viral infections after hematopoietic stem cell transplantation in Indian patients." Research Journal of Biotechnology 16, no. 10 (2021): 87–91. http://dx.doi.org/10.25303/1610rjbt8791.

Full text

Abstract:

Haematopoietic stem cell transplant (HSCT) recipients are at higher risk of morbidity and mortality due to respiratory infections and their frequency is not well studied in Indian HSCT recipients. A cohort of 55 HSCT recipients were enrolled prospectively for respiratory episodes. Real-time polymerase chain reaction was performed for respiratory viral aetiology. A total of 153 episodes of acute respiratory infections occurred, [107 episodes (mean; 2.8/patient) in autologous HSCT (n=38); 46 episodes (mean; 2.7/patients) in allogeneic HSCT (n=17)]. From these episodes, 70 samples could be tested

APA, Harvard, Vancouver, ISO, and other styles

21

Leung, Patrick, Timothy Pianta, David Langsford, Hui Sien Tay, and Rachel Cooke. "Minimal change disease following autologous stem cell transplant for Hodgkin lymphoma." BMJ Case Reports 18, no. 1 (2025): e259306. https://doi.org/10.1136/bcr-2023-259306.

Full text

Abstract:

Nephrotic syndrome is characterised by heavy proteinuria secondary to glomerular injury. It is an uncommon but serious complication of allogeneic haematopoietic stem cell transplant (HSCT), but rarely reported after autologous HSCT. Here, we report the case of a man in his mid-20s who presented with significant peripheral oedema 2 months after autologous HSCT for Hodgkin lymphoma. Investigations demonstrated nephrotic range proteinuria and hypoalbuminaemia. Renal biopsy demonstrated minimal change disease. Initial treatment with glucocorticoids was complicated by toxicity without remission. Ho

APA, Harvard, Vancouver, ISO, and other styles

22

Perreault, Sarah, Dayna McManus, Rebecca Pulk, et al. "2694. Incidence of Pneumocytis jiroveci (PJP) Infection with 3-Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT)." Open Forum Infectious Diseases 6, Supplement_2 (2019): S947. http://dx.doi.org/10.1093/ofid/ofz360.2371.

Full text

Abstract:

Abstract Background HSCT patients are at an increased risk of developing PJP after transplant due to treatment induced immunosuppression. Given the risk of cytopenias with co-trimoxazole, AP is utilized as an alternative for PJP prophylaxis. A prior study revealed a 0% (0/19 patients) incidence when AP prophylaxis was given for one year post autologous HSCT. Current guidelines recommend a duration of 3 – 6 months for PJP prophylaxis in autologous HSCT. The primary endpoint of this study was to assess the incidence of PJP infection within one year post autologous HSCT in patients who received 3

APA, Harvard, Vancouver, ISO, and other styles

23

Raza, Hasan, Sandra Naffouj, Grace Guzman, and Asim Shuja. "Autologous Gastrointestinal Graft-vs-Host Disease in a Patient With Multiple Myeloma and Hematopoietic Stem Cell Transplantation." ACG Case Reports Journal 11, no. 3 (2024): e01281. http://dx.doi.org/10.14309/crj.0000000000001281.

Full text

Abstract:

ABSTRACT Graft-vs-host disease (GVHD) of the gastrointestinal (GI) tract is notably a serious complication of allogeneic hematopoietic stem cell transplant (HSCT). However, GI GVHD has rarely been reported in autologous HSCT, and the pathophysiology remains unclear. Diagnosing GVHD after autologous HSCT requires a high level of clinical suspicion, given its nonspecific clinical presentation and endoscopic findings necessitating a histological diagnosis for confirmation. We present a case of autologous GVHD involving the GI tract in a patient with multiple myeloma who responded well to corticos

APA, Harvard, Vancouver, ISO, and other styles

24

Brás, Gil, Carlos Vaz, Luís Leite, et al. "Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma in Relapse after Autologous Transplantation: A Single Institution Experience with Matched Related Donors." Blood 128, no. 22 (2016): 5873. http://dx.doi.org/10.1182/blood.v128.22.5873.5873.

Full text

Abstract:

Abstract INTRODUCTION: Relapse in Multiple Myeloma (MM) comprises a dismal prognosis. The proteasome inhibitors and immunomodulators increased the median overall survival (OS) in relapse from 12 to 24 months. For relapsing patients, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) and also allogeneic HSCT have been considered valid options in recent consensus statement. The major concern about allogeneic HSCT is the high transplant-related mortality (TRM) even with Reduced Intensity Conditioning (RIC). AIMS: Single institution retrospective evaluatio

APA, Harvard, Vancouver, ISO, and other styles

25

Dickinson, John D., Fausto Loberiza, Victoria Whalen, et al. "Outcomes of Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)." Blood 110, no. 11 (2007): 3045. http://dx.doi.org/10.1182/blood.v110.11.3045.3045.

Full text

Abstract:

Abstract Considerable advancements have been made in our understanding of the biology and treatment of CLL/SLL. Despite these advances, CLL/SLL essentially remains an incurable illness. Hematopoietic stem cell transplantation (HSCT) has been used in an attempt to improve remission duration and survival. However little high level data exists on outcomes for patients (pts) undergoing HSCT for CLL/SLL. We evaluated the long-term survival of 65 CLL/SLL pts who underwent allogeneic or autologous HSCT from 1995 until 2006 at the University of Nebraska Medical Center. The median duration of follow-up

APA, Harvard, Vancouver, ISO, and other styles

26

Potter, Ashley, Bradley Beck, and Surachat Ngorsuraches. "Tbo-filgrastim versus filgrastim for stem cell mobilization and engraftment in autologous hematopoietic stem cell transplant patients: A retrospective review." Journal of Oncology Pharmacy Practice 26, no. 1 (2019): 23–28. http://dx.doi.org/10.1177/1078155219833444.

Full text

Abstract:

Introduction Filgrastim, a granulocyte colony-stimulating factor, is commonly used in autologous hematopoietic stem cell transplants (HSCTs) to assist with peripheral blood progenitor cell (PBPC) collection and to support stem cell engraftment. In the United States, tbo-filgrastim is approved under its own Biologic License Application and is limited to a single indication excluding the HSCT population. Methods Approximately one year after a system-wide formulary change to tbo-filgrastim for all on- and off-label indications, our institution conducted an IRB-approved retrospective comparison of

APA, Harvard, Vancouver, ISO, and other styles

27

Roerden, Malte, Stefan Wirths, Martin Sökler, Wolfgang A. Bethge, Wichard Vogel, and Juliane S. Walz. "Impact of Mantle Cell Lymphoma Contamination of Autologous Stem Cell Grafts on Outcome After High-Dose Chemotherapy." Cancers 13, no. 11 (2021): 2558. http://dx.doi.org/10.3390/cancers13112558.

Full text

Abstract:

Novel predictive factors are needed to identify mantle cell lymphoma (MCL) patients at increased risk for relapse after high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HDCT/Auto-HSCT). Although bone marrow and peripheral blood involvement is commonly observed in MCL and lymphoma cell contamination of autologous stem cell grafts might facilitate relapse after Auto-HSCT, prevalence and prognostic significance of residual MCL cells in autologous grafts are unknown. We therefore performed a multiparameter flow cytometry (MFC)-based measurable residual disease (MRD) a

APA, Harvard, Vancouver, ISO, and other styles

28

Johnson, Mary Anbarasi. "Nursing Care of Adolescents Undergoing HSCT." Journal of Healthcare and Advanced Nursing 2, no. 1 (2024): 1–4. http://dx.doi.org/10.59462/jhan.2.1.107.

Full text

Abstract:

Autologous bone marrow transplant (ABMT), also known as autologous hematopoietic stem cell transplant (HSCT), is a medical procedure where a patient’s own stem cells are collected and later infused back into the patient after high-dose chemotherapy or radiation. This procedure is often used in the treatment of certain cancers, such as neuroblastoma or leukemia, as well as certain non-malignant conditions. Nursing care for a child undergoing autologous bone marrow transplant involves various aspects of physical, emotional and psychosocial support. Here are some key nursing considerations Pre-tr

APA, Harvard, Vancouver, ISO, and other styles

29

Khaled, Yasser, Koji Kato, John E. Levine, et al. "Superior Long Term Progression Free Survival of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Compared to Autologous Hematopoietic Stem Cell Transplantation after Identical Conditioning Regimen." Blood 110, no. 11 (2007): 3031. http://dx.doi.org/10.1182/blood.v110.11.3031.3031.

Full text

Abstract:

Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) is a treatment option with curative potential that exploits graft versus myeloma effect (GVM). However, myeloablative allogeneic HSCT has been associated with high transplant-related mortality and its impact on risk of relapse has been questioned. The differences in conditioning regimens, GVHD prophylaxis and short follow up have limited our ability to assess the impact of GVM when comparing allogeneic and autologous HSCT. Method: We evaluated the long term outcomes of 74 consecutive patients under the age of 60 who underwent a

APA, Harvard, Vancouver, ISO, and other styles

30

Miller, Paul D. E., Alice S. Forster, Thushan I. de Silva, et al. "Sociodemographic and psychological determinants of influenza vaccine intention among recipients of autologous and allogeneic haematopoietic stem cell transplant: a cross-sectional survey of UK transplant recipients using a modified health belief model." BMJ Open 8, no. 8 (2018): e021222. http://dx.doi.org/10.1136/bmjopen-2017-021222.

Full text

Abstract:

ObjectivesStudies exploring vaccination rates among haematopoietic stem cell transplant (HSCT) recipients have focused on physician factors that limit uptake. Understanding the patient factors that determine vaccination intention is crucial to delivering a successful vaccination programme. Using a modified health belief model (mHBM), we conducted a cross-sectional survey with the objective of exploring the sociodemographic and psychological factors that determined autologous and allogeneic HSCT recipients’ intention to receive the seasonal inactivated influenza vaccine (SIIV) during the 2015–2

APA, Harvard, Vancouver, ISO, and other styles

31

Daikeler, Thomas, Myriam Labopin, Massimo Di Gioia, et al. "Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party." Blood 118, no. 6 (2011): 1693–98. http://dx.doi.org/10.1182/blood-2011-02-336156.

Full text

Abstract:

Abstract To specify the incidence and risk factors for secondary autoimmune diseases (ADs) after HSCT for a primary AD, we retrospectively analyzed AD patients treated by HSCT reported to EBMT from 1995 to 2009 with at least 1 secondary AD (cases) and those without (controls). After autologous HSCT, 29 of 347 patients developed at least 1 secondary AD within 21.9 (0.6-49) months and after allogeneic HSCT, 3 of 16 patients. The observed secondary ADs included: autoimmune hemolytic anemia (n = 3), acquired hemophilia (n = 3), autoimmune thrombocytopenia (n = 3), antiphospholipid syndrome (n = 2)

APA, Harvard, Vancouver, ISO, and other styles

32

Ruiz, Milton A., Maria Carolina Oliveira, Daniela Moraes, et al. "Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases." JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY 4, no. 1 (2023): 182. http://dx.doi.org/10.46765/2675-374x.2023v4n1p182.

Full text

Abstract:

Autoimmune diseases are an important field for the development of hematopoietic stem cell transplantation (HSCT). The Brazilian Society for Cellular Therapy and Bone Marrow Transplantation (Sociedade Brasileira de Terapia Celular e Transplante de Medula Óssea, SBTMO) organized consensus meetings for the Autoimmune Diseases Group, to review the available literature on HSCT for autoimmune diseases, aiming to gather data that support the procedure for these patients. Three autoimmune diseases for which there are evidence-based indications for HSCT are multiple sclerosis, systemic sclerosis and Cr

APA, Harvard, Vancouver, ISO, and other styles

33

Holdreith, Nicholas, Grace Lee, Vemika Chandra, et al. "LNK (SH2B3) inhibition expands healthy and Fanconi anemia human hematopoietic stem and progenitor cells." Blood Advances 6, no. 3 (2022): 731–45. http://dx.doi.org/10.1182/bloodadvances.2021004205.

Full text

Abstract:

Abstract Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for a variety of hematological diseases. Allogenic HSCT requires hematopoietic stem cells (HSCs) from matched donors and comes with cytotoxicity and mortality. Recent advances in genome modification of HSCs have demonstrated the possibility of using autologous HSCT-based gene therapy to alleviate hematologic symptoms in monogenic diseases, such as the inherited bone marrow failure (BMF) syndrome Fanconi anemia (FA). However, for FA and other BMF syndromes, insufficient HSC numbers with functional defect

APA, Harvard, Vancouver, ISO, and other styles

34

Gesundheit, Benjamin, Reuven Or, Einat Budowski, et al. "The Rate of Cytomegalovirus Infection and Disease in Correlation with the Type of Hematopoietic Stem Cell Transplantation in the Era of Preemptive Antiviral Therapy." Blood 112, no. 11 (2008): 4347. http://dx.doi.org/10.1182/blood.v112.11.4347.4347.

Full text

Abstract:

Abstract Background: Despite diagnostic and therapeutic advances, cytomegalovirus (CMV) has remained a significant complication after hematopoietic stem cell transplantation (HSCT). The widespread use of preemptive antiviral therapy has reduced the occurrence of early CMV disease and changed its epidemiology. In order to define the current trends and to establish future guidelines, we retrospectively analyzed the rate of CMV infection and disease in the following types of HSCT: autologous HSCT, fully matched-, mismatched- and haploidentical-allogeneic HSCT. Patients & Methods: Patients rec

APA, Harvard, Vancouver, ISO, and other styles

35

Mahfuz, Huque, Mohammed Mosleh Uddin, Md Mostafil Karim, Mohammad Elias Hossain, and Amin Islam. "Haematopoietic Stem Cell Transplantation: A Single Center Experience of Four Years in Bangladesh." Journal of Bangladesh College of Physicians and Surgeons 40, no. 3 (2022): 146–52. http://dx.doi.org/10.3329/jbcps.v40i3.60299.

Full text

Abstract:

Background: Haematopoietic stem cell transplantation (HSCT) is the standard consolidation therapy for a variety of malignant and non-malignant diseases in children and adults. Our experience of HSCT in 26 patients with various indications is shared in this article. Materials and methods: This was a retrospective analysis of first 26 patients who had undergone autologous and allogeneic transplant at our center, with M:F=2.7:1. The mean age for autologous transplant was 45 years (range 23-57 years). The median follow-up period was 23 months 25 days (range 3to 47 months).The data was obtained car

APA, Harvard, Vancouver, ISO, and other styles

36

Williams, Loretta A., Karen O. Anderson, Xin Shelley Wang, et al. "Patterns of Symptom Burden in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation." Blood 114, no. 22 (2009): 1396. http://dx.doi.org/10.1182/blood.v114.22.1396.1396.

Full text

Abstract:

Abstract Abstract 1396 Poster Board I-418 Introduction: Hematopoietic stem cell transplantation (HSCT) is an intensive therapy that may cure or control a variety of hematological malignancies. Although the toxicities associated with HSCT are well-described, patient report of symptom burden is rarely addressed. Lack of understanding of symptoms may result in failure to address symptoms and return patients to optimum functioning. Differences in the pattern of symptom burden between autologous (auto) and allogeneic (allo) HSCT and the special needs for symptom management that each type of therapy

APA, Harvard, Vancouver, ISO, and other styles

37

Shah, Chirag A., Arun Karanwal, Maharshi Desai, Munjal Pandya, Ravish Shah, and Rutvij Shah. "Hematopoietic Stem-Cell Transplantation in the Developing World: Experience from a Center in Western India." Journal of Oncology 2015 (2015): 1–9. http://dx.doi.org/10.1155/2015/710543.

Full text

Abstract:

We describe our experience of first 50 consecutive hematopoietic stem-cell transplants (HSCT) done between 2007 and 2012 at the Apollo Hospital, Gandhinagar, 35 autologous HSCT and 15 allogeneic HSCT. Indications for autologous transplant were multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, and acute myeloid leukemia, and indications for allogeneic transplants were thalassemia major, aplastic anaemia, chronic myeloid leukemia, and acute lymphoblastic and myeloid leukaemia. The median age of autologous and allogeneic patient’s cohort was 50 years and 21 years, respectively. Median fol

APA, Harvard, Vancouver, ISO, and other styles

38

Bryant, Adam, Elizabeth Pringle, Christopher Bredeson, et al. "Autologous Stem Cell Transplant for Myasthenia Gravis: A Single-Centre Experience." Blood 124, no. 21 (2014): 3996. http://dx.doi.org/10.1182/blood.v124.21.3996.3996.

Full text

Abstract:

Abstract Myasthenia Gravis is an antibody-mediated disease that affects the neuromuscular junction. Despite advances in immune-targeted therapies, a subset of patients demonstrate refractory disease with severe or life-threatening symptoms. Disease control has been achieved using autologous hematopoietic stem cell transplant (HSCT) in a variety of autoimmune conditions including multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, stiff person syndrome, and others. Here we report our center’s experience using autologous HSCT in seven patients with myasthenia. Seven myasthenia

APA, Harvard, Vancouver, ISO, and other styles

39

Tichelli, André, Eric Beohou, Myriam Labopin, et al. "Outcome of Patients with Second Cancer after Hematopoietic Stem Cell Transplantation: On Behalf of the Complications and Quality of Life Working Party of the EBMT." Blood 128, no. 22 (2016): 3441. http://dx.doi.org/10.1182/blood.v128.22.3441.3441.

Full text

Abstract:

Abstract Background Hematopoietic stem cell transplantation (HSCT) is potentially a curative treatment for a number of life-threatening malignant and non-malignant disorders. Despite significant improvements in outcome over time, long-term survivors are at risk for late complications and their mortality remains higher than expected. Second cancers are well-known late complications, associated with substantial mortality. Although we know the incidence and risk factors for many second cancers there is a paucity of data on their outcome after HSCT. We aimed to estimate the outcome of second cance

APA, Harvard, Vancouver, ISO, and other styles

40

Huang, Haiwen, Mao Jin, Qisi Lu, Tao You, and Jingxian Gu. "Study of Autologous Versus Allogeneic Stem Cell Transplantation in 56 Patients with Advanced High-Risk Extranodal NK/T-Cell Lymphoma." Blood 144, Supplement 1 (2024): 4442. https://doi.org/10.1182/blood-2024-204661.

Full text

Abstract:

Introduction: Extranodal NK/T-cell lymphoma (ENKTL) is a rare and highly aggressive form of non-Hodgkin lymphoma (NHL) characterized by a propensity for drug resistance and poor prognosis. For patients with advanced high-risk disease, guidelines recommend stem cell transplantation as consolidation therapy following first-line induction treatment, but do not specify whether autologous or allogeneic transplantation should be performed. Previous studies have not comprehensively included ENKTL patients undergoing both autologous hematopoietic stem cell transplantation (auto-HSCT) and allogeneic he

APA, Harvard, Vancouver, ISO, and other styles

41

Yavlal, Figen, Belma Doğan Güngen, Yeşim Güzey Aras, and Yusuf Çelik. "Evaluation of pre- and post-transplant electroencephalographic examination in hematopoietic stem cell transplant patients." Ideggyógyászati szemle 76, no. 1-2 (2023): 51–57. http://dx.doi.org/10.18071/isz.76.0051.

Full text

Abstract:

Background and purpose – Haematopoietic stem cell transplantation (HSCT) is one of the most effective treatment methods for many malignant and non-malignant diseases. In this study, we aimed to detect electroencephalographic (EEG) anomalies at an early stage in patients who underwent allogeneic and autologous HSCT and required the management of potentially lifethreatening non-convulsive seizures. Methods – The study was conducted with 53 patients. The age, gender, HSCT type (allogeneic or autologous), and treatment regimens applied before and after HSCT were recorded. All patients underwent EE

APA, Harvard, Vancouver, ISO, and other styles

42

Komech, E. A., I. V. Zvyagin, M. V. Pogorelyy, I. Z. Mamedov, D. A. Fedorenko, and Y. B. Lebedev. "Characterization of the T-cell Repertoire after Autologous HSCT in Patients with Ankylosing Spondylitis." Acta Naturae 10, no. 2 (2018): 48–57. http://dx.doi.org/10.32607/20758251-2018-10-2-48-57.

Full text

Abstract:

Autologous hematopoietic stem cell transplantation (HSCT), a safer type of HSCT than allogeneic HSCT, is a promising therapy for patients with severe autoimmune diseases (ADs). Despite the long history of medical practice, structural changes in the adaptive immune system as a result of autologous HSCT in patients with various types of ADs remain poorly understood. In this study, we used high-throughput sequencing to investigate the structural changes in the peripheral blood T-cell repertoire in adult patients with ankylosing spondylitis (AS) during two years after autologous HSCT. The implemen

APA, Harvard, Vancouver, ISO, and other styles

43

Gupta, Aditya Kumar, Jagdish Prasad Meena, Rachna Seth, Priyanka Naranje, Sujata Mohanty, and Poonam Coshic. "Autologous HSCT: Achieving comparable survival with adaptations." Pediatric Hematology Oncology Journal 8, no. 4 (2023): S46—S47. http://dx.doi.org/10.1016/j.phoj.2023.10.120.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Shah, Gunjan L., Joanne Filicko-O’Hara, and Neal Flomenberg. "Absolute Lymphocyte Count As Predictor of Survival Following Hematopoietic Stem Cell Transplants." Blood 118, no. 21 (2011): 4538. http://dx.doi.org/10.1182/blood.v118.21.4538.4538.

Full text

Abstract:

Abstract Abstract 4538 Following hematopoietic stem cell transplantation (HSCT), morbidity and mortality are often related to opportunistic infection early post HSCT and it is accepted that immune reconstitution has a protective effect. Absolute lymphocyte counts (ALC) act as a surrogate for immune reconstitution. Prior studies suggest that an ALC greater than 0.5×10^9/L on day 15 post autologous HSCTs and greater than 0.3×10^9/L on day 30 post allogeneic HSCTs can prognosticate overall survival (OS) and progression-free survival (PFS). However, most of these studies have been single disease s

APA, Harvard, Vancouver, ISO, and other styles

45

Becker, Sabrina A., Julius C. Enssle, Anne C. Wilke, et al. "Characterizing the Microbiome-Immune Axis in Hematopoietic Stem Cell Recipients." Blood 144, Supplement 1 (2024): 2022. https://doi.org/10.1182/blood-2024-207279.

Full text

Abstract:

Hematologic diseases such as malignant lymphomas and multiple myelomas are potentially life-threatening diseases, that can be treated with high-dose chemotherapy (HDCT) and subsequent autologous stem cell transplantation (HSCT). However, these therapies lead to severe immunosuppression and an increased risk of infection. Recent studies have demonstrated the importance of gut microbiome diversity for treatment efficacy and preclinical data suggests a direct crosstalk between the microbiome and the immune system of the host. Although it is known that the gut microbiome can impact immune cell sub

APA, Harvard, Vancouver, ISO, and other styles

46

Adair, Jennifer E., Shaina Porter, Kevin Haworth, Kenric Tam, Hans-Peter Kiem, and Matthew H. Porteus. "Novel Integrated Autologous Hematopoietic Stem Cell Tracking in Nonhuman Primates Reveals Successive Pattern of Multi-Lineage Reconstitution after Total Body Irradiation." Blood 124, no. 21 (2014): 2910. http://dx.doi.org/10.1182/blood.v124.21.2910.2910.

Full text

Abstract:

Abstract Hematopoietic stem cell transplantation (HSCT) has been used to cure patients for over four decades, yet the kinetics and clonal dynamics of repopulation by multipotent HSCs remains unresolved. Two sequence-based methods have been used to measure HSC contribution in preclinical models, integration site (IS) analysis and DNA barcoding. Both methods are accomplished by retrovirus tagging of HSCs and each confers different methodological constraints. We hypothesized that IS analysis and DNA barcoding together would provide more robust HSCT reconstitution data if applied to the clinically

APA, Harvard, Vancouver, ISO, and other styles

47

Mineri, Rossana, Jacopo Mariotti, Barbara Sarina, et al. "Genomic integration of HHV-6 mimicking viral reactivation after autologous stem cell transplantation." Mediterranean Journal of Hematology and Infectious Diseases 10, no. 1 (2018): e2018013. http://dx.doi.org/10.4084/mjhid.2018.013.

Full text

Abstract:

The monitoring of HHV-6 after allogeneic hematopoietic stem cell transplantation (HSTC) has proven to be useful in preventing life-threatening complications; however, the pathogenic role of HHV-6 after autologous HSCT is not well-characterized, although viral reactivation might be responsible for significant complications even after autologous HSCT. Here we report for the first time to our knowledge the case of a patient with genomic integration of HHV-6, presenting with high titers of HHV-6 after autologous HSCT, mimicking HHV-6 reactivation. The presence of viral DNA in the follicle bulb con

APA, Harvard, Vancouver, ISO, and other styles

48

Orio, Francesco, Giovanna Muscogiuri, Stefano Palomba, et al. "Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells." Scientific World Journal 2014 (2014): 1–13. http://dx.doi.org/10.1155/2014/282147.

Full text

Abstract:

Early and late endocrine disorders are among the most common complications in survivors after hematopoietic allogeneic- (allo-) and autologous- (auto-) stem cell transplant (HSCT). This review summarizes main endocrine disorders reported in literature and observed in our center as consequence of auto- and allo-HSCT and outlines current options for their management. Gonadal impairment has been found early in approximately two-thirds of auto- and allo-HSCT patients: 90–99% of women and 60–90% of men. Dysfunctions of the hypothalamus-pituitary-growth hormone/insulin growth factor-I axis, hypothal

APA, Harvard, Vancouver, ISO, and other styles

49

Chiu, Jodi, Brianna Ananthan, Matthew Lawrence, et al. "Venous Thromboembolism in Hematopoietic Stem Cell Transplantation." Blood 142, Supplement 1 (2023): 4022. http://dx.doi.org/10.1182/blood-2023-180737.

Full text

Abstract:

Background: Venous thromboembolism (VTE) is an underappreciated complication seen amongst allogeneic and autologous hematopoietic stem cell transplant (HSCT) patients and a major cause of morbidity and mortality. Despite these challenges, VTE in HSCT remains understudied, with a paucity of established guidelines on thrombosis surveillance, prevention, and treatment. Balancing risk of bleeding and thrombosis is particularly challenging as HSCT patients are concurrently pancytopenic and coagulopathic. We aimed to describe the incidence, predictors, and adverse events of VTE amongst patients at 9

APA, Harvard, Vancouver, ISO, and other styles

50

Miniati, I., S. Guiducci, M. L. Conforti, et al. "Autologous stem cell transplantation improves microcirculation in systemic sclerosis." Annals of the Rheumatic Diseases 68, no. 1 (2008): 94–98. http://dx.doi.org/10.1136/ard.2007.082495.

Full text

Abstract:

Background:In systemic sclerosis (SSc) reduced capillary density decreases blood flow and leads to tissue ischaemia and fingertip ulcers. Nail fold videocapillaroscopy (NVC) is a diagnostic and follow-up parameter useful to evaluate the severity, activity and the stage of SSc microvascular damage. Autologous haemopoietic stem cell transplantation (HSCT) is a new treatment for patients with severe diffuse cutaneous systemic sclerosis (dcSSc) refractory to conventional therapies. We aimed to evaluate the improvement of microvasculature after HSCT using NVC.Methods:A total of 16 patients with sev

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!